Abstract
Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study
Journal of clinical oncology, Vol.36(15_suppl), pp.TPS4600-TPS4600
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.TPS4600
Abstract
Abstract only
Details
- Title: Subtitle
- Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study
- Creators
- Xiao X. Wei - Dana-Farber Cancer InstituteRana R. McKay - Dana-Farber Cancer InstituteKathryn P. Gray - Dana-Farber Cancer InstituteWalter Michael Stadler - University of ChicagoDavid F. McDermott - Beth Israel Deaconess Medical CenterBradley Alexander McGregor - Grant Medical CenterNeeraj Agarwal - University of UtahChristos Kyriakopoulos - University of Wisconsin Carbone Cancer CenterBenedito A. Carneiro - Northwestern UniversityTracy Lynn Rose - University of North Carolina HospitalsYousef Zakharia - University of IowaDavid A. Braun - Dana-Farber Cancer InstituteKenneth J Livak - Dana-Farber Cancer InstituteCatherine J. Wu - Dana-Farber Cancer InstituteEliezer Mendel Van Allen - Dana-Farber Cancer InstituteSabina Signoretti - Dana-Farber Cancer InstituteJoshua Michael Lang - University of Wisconsin Carbone Cancer CenterF. Stephen Hodi - Dana-Farber Cancer InstituteToni K. Choueiri - Dana-Farber Cancer InstituteLauren Christine Harshman - Stanford University
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.TPS4600-TPS4600
- DOI
- 10.1200/JCO.2018.36.15_suppl.TPS4600
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984548381702771
Metrics
3 Record Views